U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07026604) titled 'Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study' on June 10.
Brief Summary: Cerebral cavernous malformation (CCM) is a common vascular abnormality of the brain, affecting 0.1%-0.5% of people. It often causes recurrent brain hemorrhages, epilepsy, and neurological impairments, with surgery being the main treatment. However, surgery carries high risks for patients with multiple lesions or lesions in critical areas, and no effective pharmacological treatment is available. CCM is linked to mutations in genes like CCM1, CCM2, CCM3, or MAP3K3, which activate the MEK5-ERK5-KLF2/4 pathway, d...